ASLN Projected Dividend Yield

ASLAN Pharmaceuticals Ltd ( NASDAQ : ASLN )

ASLAN Pharmaceuticals is a clinical-stage immunology focused biopharmaceutical company developing treatments to transform the lives of patients. Co.'s portfolio is led by eblasakimab (also known as ASLAN004), a potential first-in-class human monoclonal antibody that binds to the interleukin (IL)-13 receptor a1 subunit, blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13 which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. Co. is also developing farudodstat (also known as ASLAN003), an orally active, inhibitor of human dihydroorotate dehydrogenase that has the potential to be a therapy in autoimmune disease.

20 YEAR PERFORMANCE RESULTS